期刊文献+

左炔诺孕酮宫内缓释系统治疗子宫内膜异位症的临床疗效 被引量:19

Clinical effect of levonorgestrel- releasing intrauterine system in the treatment of endometriosis
原文传递
导出
摘要 目的评价左炔诺孕酮宫内缓释系统(LNG-IUS)治疗子宫内膜异位症(EM)的长期安全性。方法 49例EM患者用LNG-IUS治疗,于治疗前及治疗后6,12,36,60个月,比较患者的痤疮、面部色素沉着、乳房胀痛、体毛、生活质量评分和体重等变化。结果与治疗前相比,49例患者在随访各时间点,观察体毛评分、面部色素沉着评分与体重,差异均无统计学意义(均P>0.05);生活质量和乳房胀痛评分均显著好转,差异有统计学意义(均P<0.05)。与治疗前相比,痤疮评分在治疗6个月后差异无统计学意义(P>0.05),但治疗12,36,60个月后均明显降低(均P<0.05)。结论 LNG-IUS是一种可长期治疗EM的安全性较高的治疗方法。 Objective To evaluate the safety of levonorgestrel -relea-sing intrauterine system ( LNG-IUS ) in the treatment of endometriosis ( EM) for 5 years.Methods A total of 49 patients with endometriosis were included.The LNG-IUS was inserted into uterine cavity.The ac-ne, facial pigmentation, mammary swelling, the body weight , the body hair and quality of life were scored and compared before and 6, 12, 36, and 60 months after the insertion of the LNG -IUS.Results Compared with prior treatment, the body weight and the scores of the body hair and facial pigmentation showed no marked change at each point of observation time ( P 〉0.05 ) , and the scores of quality of life and mammary swelling dropped significantly ( P〈0.05 ).Six months after insertion, the score of acne had no marked change ( P〉0.05 ) , but 12, 36, and 60 months later, it decreased significantly ( P〈0.05 ).Conclusion LNG -IUS is safe for long -term treat-ment of endometriosis.
出处 《中国临床药理学杂志》 CAS CSCD 北大核心 2014年第7期571-574,共4页 The Chinese Journal of Clinical Pharmacology
基金 新疆维吾尔自治区自然科学基金资助项目(2012211A066)
关键词 左炔诺孕酮 药物缓释系统 子宫内膜异位症 安全性 levonorgestrel drug delivery system endometriosis safety
  • 相关文献

参考文献8

二级参考文献42

共引文献213

同被引文献132

  • 1朱虹,蔡丽萍.VEGF在不同部位子宫内膜异位症中的表达及意义[J].江西医药,2013,48(4):308-311. 被引量:7
  • 2邓姗,郎景和.左炔诺孕酮宫内缓释系统的临床功用及相关基础研究[J].国外医学(妇产科学分册),2004,31(5):285-288. 被引量:148
  • 3何淑明,韦明秀,韩燕华,何立红.左炔诺孕酮宫内缓释系统治疗子宫腺肌病的临床观察[J].中华妇产科杂志,2005,40(8):536-538. 被引量:115
  • 4邓姗,郎景和,冷金花,刘珠凤,孙大为,朱兰.左炔诺孕酮宫内缓释系统用于防治子宫内膜异位症和子宫腺肌病的临床观察[J].中华妇产科杂志,2006,41(10):664-668. 被引量:71
  • 5Sheng J, Zhang WY, Zhang JP, et al. The LNG - IUS study on adenomyosis: a 3 - year follow - up study on the efficacy and side effects of the use of levonorgestrel intrauterine system for the treatment of dysmenorrhea associated with adenomyosis [ J ]. Contraception,2009, 79 (3): 189-193.
  • 6Loveless A, Dhari A, Kilpatrick CC. Perforated levonorgestrel - releasing intrauterine system resulting in small bowel obstruction: a case report [J]. J Reprod Med, 2014, 59 (11/12): 611-613.
  • 7Ji F, Yang XH, Ai Xing Zi AL, et al. Role of levonorgestrel - releasing intrauterine system in dysmenorrhea due to adenomyosis and the influence on ovarian function [ J ]. Clin Exp Obstet Gynecol, 2014, 41 (6): 677-680.
  • 8Gemzell - Danielsson K, Inki P, Boubli L, et al. Bleeding pattern and safety of consecutive use of the levonorgestrel - releasing intrauterine system (LNG -IUS) a multicentre prospective study [J]. HumReprod, 2010, 25 (2): 354-359.
  • 9Cho S, Nam A, Kim H, et al. Clinical effects of the levonorgestrel -releasing intrauterine device in patients with adenomyosis [ J J. Am J Obstet Gynecol, 2008, 198 (4): 3731-3317.
  • 10Lal S, Kriplani A, Kulshrestha V, et al. Efficacy of mifepristone in reducing intermenstrual vaginal bleeding in users of the levonorgestrel intrauterine system [J]. Int J Gynaecol Obstet, 2010, 109 (2): 128 - 130.

引证文献19

二级引证文献113

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部